Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

Solution were the result of increased volume.

Gross profit for the nine months ended September 30, 2011 was $1.92 billion and gross margins were 41.7%. For the nine months ended September 30, 2010, gross profit was $1.64 billion and gross margins were 40.8%. Gross profit for the current year-to-date period is impacted by certain purchase accounting related items, of approximately $278.1 million, which consisted primarily of amortization related to purchased intangible assets associated with acquisitions. Excluding such items, gross margins would have been approximately 48%. Prior year gross profit is also impacted by similar purchase accounting related items in the amount of $217.6 million. Excluding such items, gross margins in the prior year would have been approximately 46%. This increase in gross margin is primarily the result of new product launches in North America and favorable pricing on the EpiPen® Auto-Injector.  

Earnings from operations were $758.1 million for the nine months ended September 30, 2011, compared to $627.4 million for the comparable prior year period.  Excluding the impact of purchase accounting related items in both periods, as mentioned above, earnings from operations increased to $1.04 billion in the current nine-month period from $845.0 million in the prior year comparable period, mainly due to an increase in gross profit, as a result of an increase in revenues and gross margin improvement, partially offset by increases in R&D and SG&A expense. Also included in the current nine-month period is $28.5 million of net expense related to the settlement of litigation.  In the comparable prior year period, Mylan recognized net expense from litigation settlements of $14.3 million.  

Interest expense for the nine months ended September 30, 2011, totaled $254.8 million, compared to $240.0 million for comparable prior year period. The increase is primarily due to interest as
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 The paradigm of ... biological systems that can help predict the adverse and ... Sergey Stepaniants, Head of Computational Biology at the Genomics ... tools to ensure high-quality genomics when used as part ... applied to complex data sets to identify key clinical ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Milestone Validates Approach, SAN FRANCISCO, January 22 ... its first clinical trial, a,proof-of-concept study that evaluated ... blocker. Rufinamide was discovered and,developed by Novartis and ... a,drug to treat a form of epilepsy. This ...
... B.V. announced today the closure of its Series ... Ventures., Progentix Orthobiology B.V. was established in ... products for clinical application,in bone regenerative surgery. Progentix ... biomaterial scaffolds that have the ability to,attract growth ...
... NorTech Venture,Capital Advisory Task Force reported in its inaugural ... generate and attract over $1.2 billion,in venture capital by ... companies,located in Northeast Ohio. According to the findings from ... region, to be,released in print mid February, Northeast Ohio ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
(Date:5/16/2013)... the stability of today,s largest ice sheets in Greenland and ... ago, for example when Earth was going through a ... high sea level due to ice sheet collapse at that ... if the world,s largest ice sheets collapsed in the past, ... progressively warming world. , However, a new groundbreaking study ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2
... Autism Speaks, the nation,s largest autism science and advocacy ... to investigate genetic and environmental risk factors for autism. ... multi-site studies focusing on a collaborative prospective study of ... who are at higher genetic risk for developing the ...
... legs learned to walk upright. So did Faith, ... "half-man" born without legs, grew naturally into a graceful hand-walker. ... Hensel live successfully with separate heads connected to a single ... to drive, swim, shuffle cards and play piano. In ...
... that modern lifestyle habits may play a bigger role than ... A review of the scientific evidence over the past 150 ... hygiene and health education, may override the effects of food ... a Supplement to the journal Obesity Reviews . ...
Cached Biology News:Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 2Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 3Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 4Autism Speaks funds $5 million to studies on genetic and environmental risk factors for autism 5'Freaks' help scientist unravel nature and nurture 2'Freaks' help scientist unravel nature and nurture 3
Candida (IgG) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... RNase III, used with its manganese-containing reaction ... heterogeneous mix of short (1825 bp) interfering ... mammalian cells. 1.3 units (1 l) of ... 1 g of dsRNA into siRNA suitable ...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
Biology Products: